SML3476

Brivaracetam

≥98% (HPLC)

• Synonym(s): (αS,4R)-α-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide, (2S)-2-[(4R)-2-Oxo-4-propylpyrrolidin-1-yl]butanamide, (S)-2-((R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide, UCB 34714, UCB-34714, UCB34714
• Empirical Formula (Hill Notation): C₁₁H₂₀N₂O₂
• CAS Number: 357336-20-0
• Molecular Weight: 212.29
• UNSPSC Code: 12352200
• NACRES: NA.77
• MDL number: MFCD25976668
• Assay: ≥98% (HPLC)
• Form: powder

Properties

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• drug control: USDEA Schedule V
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: -10 to -25°C

Description

Biochem/physiol Actions

Brivaracetam shows approximately 10 times greater potency than levetiracetam (Keppra)*; pIC50 at LBS = 7.0; inhibits audiogenic seizures in seizure-prone mice (ED50 = 14 μmol/kg) and is also effective in other animal models of epilepsy. Brivaracetam is used as an anticonvulsant (antiepileptic) for seizure treatment.

Orally active levetiracetam analog with higher synaptic vesicle protein 2A (SV2A) affinity and >10 times greater in vivo antiseizure efficay.

Safety Information

• Storage Class: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable